SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., announced that it will hold a conference call on Monday, October 27, 2008 at 4:30 p.m. (Eastern Time) to discuss the clinical use of Monogram's Trofile(TM) Assay in conjunction with Pfizer's CCR5 antagonist, Selzentry(TM). Monogram will also review its third quarter 2008 financial results. The call will be hosted by William D. Young, Chairman & CEO of Monogram. Dr. David Hardy will participate in the call. Dr. Hardy is Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and is Associate Professor of Medicine-in-Residence at the David Geffen School of Medicine at UCLA.
To participate in the live teleconference, please call (877) 604-9672, or (719) 325-4896 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available on the Investor Relations section at http://www.monogrambio.com. Following the live broadcast, a replay of the call will also be available at (888) 203-1112 or (719) 457-0820 for international callers, through Sunday, November 9, 2008. The replay passcode is 4461917. The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at www.monogrambio.com.
Trofile is a trademark of Monogram Biosciences, Inc. Selzentry is a trademark of Pfizer Inc.
CONTACT: Alfred G. Merriweather, Chief Financial Officer of Monogram
Biosciences, Inc., +1-650-624-4576, amerriweather@monogrambio.com; or
Jeremiah Hall of Feinstein Kean Healthcare for Monogram Biosciences, Inc.,
+1-415-677- 2700, jeremiah.hall@fkhealth.com
Web site: http://www.monogrambio.com/
